Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
MI and Non-obstructive Coronary Arteries
Author(s): Yetunde A Fatade , Noah A Newman , Nidhi H Patel , et al Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 8 months ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
FIRE Trial: Sustained Benefit of Complete Revascularization in Older MI Patients at 3 Years
Added: 4 months ago Source:  Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time… View more

Demographic

Heart Failure
ESC 25: LipoaScreen: Cascade Screening for LP(a)
Author(s): Jonas Brinck Added: 5 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 2 years ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
ACC.24: FFR or Culprit-Only PCI in STEMI
Author(s): Felix Böhm Added: 1 year ago
ACC.24 — Investigator, Dr Felix Böhm (Danderyd Hospital, SE) joins us to discuss the findings from a study investigating fractional flow reserve-guided complete or culprit-only percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (MI).1542 patients were enrolled in the trial, who were randomized 1:1 to receive either FFR-guided PCI of non-culprit lesions… View more

Intervention

MI/ACS
Author(s): Alexander Fanaroff Added: 1 year ago
ACC.24 — Dr Alexander Fanaroff (Penn Medicine, US) joins us onsite at ACC.24 to discuss the findings from the BE ACTIVE study, which investigated behavioural economic approaches to increasing physical activity (PA) in patients with an elevated risk of cardiovascular disease (NCT03911141).This randomized, controlled trial enrolled 1062 patients with a 10-year atherosclerotic cardiovascular risk… View more

Prevention & Chronic Conditions
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 5 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
ESC 23: New Guidelines For the Management of Acute Coronary Syndromes
Author(s): Robert A Byrne Added: 2 years ago
ESC 2023 — Dr Robert Byrne (Mater Private Hospital, Dublin, IE) joins us on-site to discuss the new guidelines from the ESC covering the management of acute coronary syndromes. Acute Coronary Syndrome (ACS) is a broad spectrum of conditions, and the presentation can vary from a stable patient, to a patient who is critically ill. In the past, separate guidelines were issued for ST-Elevation… View more

Guidelines & Statements

MI/ACS